Corporate Action Notice

September 21, 2017

Ratio Change & Reverse Stock Split

Mitsui OSK Lines, Ltd. – Ratio Change and Reverse Stock Split

DR CUSIP 60685L109 DR ISIN: US60685L1098

DR Ticker Symbol: MSLOY

Ratio (DSs: Underlying Share): 1: 3

Please be advised that Mitsui OSK Lines, Ltd. has announced a one (1) for ten (10) reverse split on its ordinary shares in the local market effective October 1, 2017.

As a result, BNY Mellon will effect a ratio change on Mitsui OSK Lines, Ltd. Depositary Receipt ("DR") program. The ratio will change from one (1) DS representing three (3) Ordinary Shares to the new ratio of two (2) DSs representing one (1) Ordinary Share. The ratio change will occur simultaneously with a reverse stock split on the Mitsui OSK Lines, Ltd., Ltd. DSs on the basis of 3 new DSs for every 5 old DSs held.

Effective October 4, 2017, DR holders of Mitsui OSK Lines, Ltd. are required on a mandatory basis to surrender their DR(s) for cancellation and exchange their "Old" DRs (CUSIP 60685L109) for "New" DRs (CUSIP: 60685L208). DR holders will receive 3 "New" Depositary Shares (DS) (CUSIP 60685L208) for every five (5) "Old" DS (CUSIP 60685L109). Only whole DSs will be distributed.

Below are the pertinent details:

DR Effective Date: October 4, 2017

Old CUSIP: 60685L109

Old Ratio: 1 DS: 3 Ordinary Shares
Exchange Ratio: 3 New DSs for every 5 Old DSs

New CUSIP: 60685L208

New DR Ratio: 2 DSs: 1 Ordinary Share

Cancellation Fee: \$0.02

Please note: A ratio change may impact the fees payable by DR investors.

BNY Mellon's books will be closed for issuances and cancellations on CUSIP 60685L109 as of the close of business September 29, 2017 and will reopen on October 4, 2017

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

NEW YORK LONDON

Ravi Davis Jacek Jankowski
Richard J Maehr Vice President
+ 1 212 815 2267 + 44 207 163 7427

adrdesk@bnymellon.com <u>jacek.jankowski@bnymellon.com</u>

BNY Mellon is providing this information for general informational purposes only and does not warrant or guarantee the accuracy, timeliness or completeness of this information. BNY Mellon does not undertake any obligation to update or amend this information. BNY Mellon provides no advice, recommendation or endorsement with respect to any company or securities. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities. BNY Mellon collects fees from Depositary Receipt ("DR") holders pursuant to the terms and conditions of the DRs. BNY Mellon may make payments to sponsored DR issuers to reimburse and /or share revenue from the fees collected from DR holders, or waive fees and expenses for services provided. BNY Mellon may pay a rebate to brokers in connection with unsponsored DR issuances. BNY Mellon may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. BNY Mellon may execute DR foreign currency transactions itself or through its affiliates and in such cases it acts as principal counterparty and not as agent, advisor, broker or fiduciary. BNY Mellon has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY Mellon earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account. The methodology used by BNY Mellon to determine DR conversion rates is available to registered Owners upon request or at https://www.adrbnymellon.com/us/en/news-and-publications/dr-issuers/asset_upload_file49220_197380.pdf. Depositary Receipts are not insured by the FDIC or any other government agency, are not deposits or other obligations o

